Aliskiren is a direct rennin inhibitor which blocks the RAAS at the first stage, decreases the activity of rennin, prevents the conversion of angiotensinogen to Ang and reduces the generation of Ang II and ALD to execute its role for the treatment of hypertension (Anderson, 2007; Politi et al., 2011). Here, AGT is linked to hypertensive disorder.